#psilocybin – “A privately-owned Canadian pharmaceutical company is one step closer to commercializing a treatment for anorexia that uses psilocybin.

Xpira Pharmaceuticals will initiate a Phase 2a clinical trial looking at the efficacy of psilocybin-assisted therapeutic protocols in patients suffering from anorexia after receiving approval from the U.S. Food and Drug Administration for its first Investigational New Drug application.

The Toronto-based firm said it aims to contribute to the successful outcome of treatment for patients with anorexia, including enhancing patients’ quality of life by furthering the development of its psilocybin-assisted treatment.”


Courtesy of the National Law Review

#cannabispolitics – “Governor Gavin Newsome signed into law September 19, 2022 several measures relating to marijuana, including one that prohibits employment discrimination based on off-duty use of marijuana.  The law takes effect on January 1, 2024.

The law will prohibit an employer from discriminating against a person in hiring, termination, or any term or condition of employment, if the discrimination is based on:

The person’s use of cannabis off the job and away from the workplace. This paragraph does not prohibit an employer from discriminating in hiring, or any term or condition of employment, or otherwise penalize a person based on scientifically valid preemployment drug screening conducted through methods that do not screen for nonpsychoactive cannabis metabolites.

An employer-required drug screening test that has found the person to have nonpsychoactive cannabis metabolites in their hair, blood, urine, or other bodily fluids.

The law further notes that:

Tetrahydrocannabinol (THC) is the chemical compound in cannabis that can indicate impairment and cause psychoactive effects.  After THC is metabolized, it is stored in the body as a nonpsychoactive cannabis metabolite.  These metabolites do not indicate impairment, only that an individual has consumed cannabis in the last few weeks. . . . While there is consensus that an employee should not arrive at a worksite high or impaired, when most tests are conducted for cannabis, the results only show the presence of the nonpsychoactive cannabis metabolite and have no correlation to impairment on the job.

As science has improved, employers now have access to multiple types of tests that do not rely on the presence of nonpsychoactive cannabis metabolites.  These alternative tests include impairment tests, which measure an individual employee against their own baseline performance and tests that identify the presence of THC in an individual’s bodily fluids.”


#californiacannabis – “The city of Sacramento paid nearly $700,000 to settle a lawsuit that claimed it charged exorbitant fines to predominantly Asian landlords whose tenants grew marijuana in their homes.

The settlement agreement, which the city signed in August, includes $650,000 in attorney’s fees, $35,000 to repay fines the property owner had paid, and roughly $10,000 in additional compensation….

Sacramento allows residents to have up to six pot plants. People who have more than that can be fined up to $500 per plant — a policy that’s still in place.

“Sacramento may have had good intentions, but its ordinance and enforcement have veered far from the guardrails imposed by law,” read the lawsuit, filed in September 2019 in Sacramento Superior Court. “Sacramento’s ordinance is unlawful. The way Sacramento Police enforces the unlawful ordinance is unlawful. The hearings that Sacramento gives owners who try to contest the wild penalty amounts are an outright abuse of power and a violation of the public trust. If Sacramento wants homeowners to respect rules, Sacramento must also respect the rules.””